Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

A new study published in the Journal of American Medical Association showed that reduced right ventricular ejection fraction ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

Now Scherr and his colleagues have found that, while the heart shows some evidence of impairment right after a race, it quickly heals. And there are no long-term negative effects after 10 years of ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approv ...